| Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy TG von Lueder, BH Wang, AR Kompa, L Huang, R Webb, P Jordaan, ... Circulation: Heart Failure 8 (1), 71-78, 2015 | 350 | 2015 |
| Pharmacodynamic and pharmacokinetic profiles of sacubitril/valsartan (LCZ 696) in patients with heart failure and reduced ejection fraction Z Kobalava, Y Kotovskaya, O Averkov, E Pavlikova, V Moiseev, D Albrecht, ... Cardiovascular therapeutics 34 (4), 191-198, 2016 | 106 | 2016 |
| Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trials AN Mead, HR Amouzadeh, K Chapman, L Ewart, A Giarola, SJ Jackson, ... Regulatory Toxicology and Pharmacology 80, 348-357, 2016 | 61 | 2016 |
| Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor SP Ayalasomayajula, TH Langenickel, P Jordaan, W Zhou, P Chandra, ... European journal of clinical pharmacology 72, 1065-1073, 2016 | 51 | 2016 |
| Disposition and metabolism of [14C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects J Flarakos, Y Du, T Bedman, Q Al-Share, P Jordaan, P Chandra, ... Xenobiotica 46 (11), 986-1000, 2016 | 46 | 2016 |
| Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease M Hinder, A Frick, P Jordaan, G Hesse, A Gebauer, J Maas, A Paccaly Clinical Pharmacology & Therapeutics 80 (6), 691-702, 2006 | 41 | 2006 |
| Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis BH Wang, TG von Lueder, AR Kompa, L Huang, R Webb, P Jordaan, ... International Journal of Cardiology 186, 104-105, 2015 | 36 | 2015 |
| Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization TH Langenickel, P Jordaan, J Petruck, K Kode, P Pal, S Vaidya, ... European journal of clinical pharmacology 72, 917-924, 2016 | 24 | 2016 |
| Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: effect on ANP, BNP, NT … Z Kobalava, O Averkov, I Meray, L Alexandriya, V Moiseev, D Albrecht, ... EUROPEAN HEART JOURNAL, 2011 | 23 | 2011 |
| Cardiotoxic potential of hydroxychloroquine, chloroquine and azithromycin in adult human primary cardiomyocytes P Jordaan, B Dumotier, M Traebert, PE Miller, A Ghetti, L Urban, ... Toxicological Sciences 180 (2), 356-368, 2021 | 22 | 2021 |
| Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: a single‐center, phase I, randomized, four‐way crossover study A Breitschaft, K Hu, C Darstein, M Ligueros‐Saylan, P Jordaan, D Song, ... The Journal of Clinical Pharmacology 54 (1), 75-86, 2014 | 20 | 2014 |
| Assessment of drug interaction potential between LCZ696, an angiotensin receptor neprilysin inhibitor, and digoxin or warfarin S Ayalasomayajula, P Jordaan, P Pal, P Chandra, D Albrecht, ... Clin Pharmacol Biopharm 4 (147), 2, 2015 | 16 | 2015 |
| Pharmacokinetics of pipamperone from three different tablet formulations GE Potgieter, G Groenewoud, PJ Jordaan, HKL Hundt, R Schall, ... Arzneimittelforschung 52 (06), 430-434, 2002 | 15 | 2002 |
| First experience with concomitant AT1 and neprilysin (NEP 24.11) inhibition with LCZ696 in patients with chronic heart failure Z Kobalava, E Pavlikova, O Averkov, V Moiseev, D Albrecht, A Feng, ... Circulation 122 (suppl_21), A19378-A19378, 2010 | 11 | 2010 |
| Autonomic correlates of late infarct artery patency after first myocardial infarction O Odemuyiwa, P Jordaan, M Malik, T Farrell, A Staunton, J Poloniecki, ... American Heart Journal 125 (6), 1597-1600, 1993 | 11 | 1993 |
| Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ … TG von Lueder, BH Wang, AR Kompa, L Huang, R Webb, P Jordaan, ... Circulation Research 107, 1071-1082, 2010 | 10 | 2010 |
| A pooled analysis of three randomized phase i/iia clinical trials confirms absence of a clinically relevant effect on the QTc Interval by Umibecestat SV Vormfelde, N Pezous, G Lefèvre, C Kolly, U Neumann, P Jordaan, ... Clinical and Translational Science 13 (6), 1316-1326, 2020 | 8 | 2020 |
| Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies R Pivonello, G Muscogiuri, G Holder, M Paul, S Sarp, A Lesogor, ... Endocrine 60, 65-72, 2018 | 8 | 2018 |
| Analysis of unipolar electrograms in rabbit heart demonstrated the key role of ventricular apicobasal dispersion in arrhythmogenicity N Guérard, P Jordaan, B Dumotier Cardiovascular toxicology 14, 316-328, 2014 | 7 | 2014 |
| An open-label, single dose study to investigate the absorption, distribution, metabolism, and elimination of [14C]-LCZ696 and its metabolites in healthy male subjects Y Du, P Chandra, Q Alshare, P Jordaan, T Langenickel, P Pal, G Sunkara, ... Poster session presented at: 2013 AAPS Annual Meeting and Exposition, 10-14, 2013 | 7 | 2013 |
